CClinicalTrials.gg
CompletedNCT00666432Updated May 3, 2021

Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes

An observational study in Schizophrenia and Bipolar, sponsored by University of Maryland, Baltimore. Completed at 6 sites in United States. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-03.

Sponsored by University of Maryland, Baltimore · Observational

Study type
Observational
Model
Family-based
Time perspective
Other
Enrollment
3,500
Ages
15 Years and older
Sex
All
01

Study summary

Briefly, this multisite study is designed to identify endophenotypes (i.e., heritable biomarkers) associated with either schizophrenia or bipolar disorder alone, or both together. The subsequent genetic analyses will search genomic loci and candidate genes associated with each of the independent endophenotypes. This is a five site study that is slotted for NIMH funding.

Read the detailed description

We propose to recruit 100 case probands with a diagnosis of SZ, 100 case probands with a diagnosis of BP Disorder I with history of psychosis; BPI-P) and 400 1st degree case relatives. All 1st degree family members who are willing to participate will provide clinical information and blood sample, only a proportion will be eligible for endophenotypic studies). Individuals with psychotic disorder not otherwise specified are also eligible for testing. Their data will be incorporated with the schizophrenia or bipolar data upon confirmation of diagnosis. Family members of individuals with psychotic disorder not otherwise specified will not be tested unless the individual has a later confirmed diagnosis of schizophrenia or bipolar disorder. Probands will not be tested during the acute phase of the illness as judged clinically e.g., significant increase in core symptoms from their stable baseline that requires a change in treatment such increased dose of medication, drug change, or hospitalization). As part of another existing protocol, we have collected most of the endophynotypic information in schizophrenia probands and 1st degree relatives other than brain imaging and few other tests. We will attempt to recruit these subjects to complete the imaging studies and the data will be used in the current study.

We will recruit 100 healthy comparison subjects from the community in order to describe the distribution of normal values for our endophenotype procedures in a demographically matched sample. The SZ and BPI-P probands, and 50 healthy control subjects, will be frequency matched on age, sex ratio, and head of the household's socio-economic status (SES). Another group of 50 healthy control subjects will be similarly matched to the relative groups recruited.

Participants will undergo a number of clinical, electrophysiological, structural brain imaging, perceptual, and cognitive assessments. These data will be used to identify phenotypes likely to be associated with genetic risk for schizophrenia and/or bipolar disorder, and to determine how these phenotypes aggregate in families. Some of the analyses will focus on examining associations between candidate genes and these alternative phenotypes. Thus if we are not able to recruit relatives we may still collect these phenotypic data in probands and their genetic sample for future genotype/phenotype association studies. Family members may elect to participate only in the clinical and blood draw portions of the study. Testing procedures require a 12 -15 hour time commitment and testing will be completed over 2 or more days. Participants will be asked to give a blood (or saliva if difficult to obtain blood sample for instance because of fear of blood draws), which will be stored for future genetic analyses. Data from the previous family study will be combined with the data collected in this protocol for some of the analyses.

02

Conditions studied

  • Schizophrenia
  • Bipolar

Browse trials for

Keywords

  • schizophrenia
  • bipolar
  • eye movements
  • phenotype
  • biochemical
  • relatives
03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

This study's planned enrollment of 3,500 is above the median of 178 across 491 observational studies indexed under Schizophrenia.

Browse Schizophrenia studies →

Lead sponsor

University of Maryland, Baltimore is the lead sponsor of 687 studies on the registry; 130 are open to participants now.

Of its 90 completed or terminated interventional studies of FDA-regulated products, 63 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects will be recruited from the University of Maryland, Community Mental Health Center and Private Psychiatrists.

Inclusion criteria

  • Male and female participants 15 years of age and above.
  • Case probands will include individuals who meet DSM-IV criteria for schizophrenia, schizoaffective, or bipolar disorder with psychosis

Exclusion criteria

Exclusion Criteria:

  • Control subjects who meet DSM-IV criteria for any lifetime psychotic illness or BP, or have a family history of psychotic or BP disorders in their first or second-degree relatives will be excluded.
  • A number of exclusions are necessary because they potentially affect neurophysiological measures. Exclusions will be applied to all groups to maintain consistency in recruitment. As a result, the following individuals will be excluded:
  • Subjects under 15 years of age will be excluded. Subjects with serious medical, neuro-ophthalmological or neurological illness (e.g., cancer, seizure disorders, encephalopathy) will be excluded, with the exception of family member subjects participating for clinical interview and blood sample only.
  • Subjects with current substance abuse (within 6 months), dependence within 2 years or extensive history of drug dependence will be excluded, with the exception of family member subjects participating for clinical interview and blood sample only.
  • Subjects with mental retardation will be excluded, with the exception of family member subjects participating for clinical interview and blood sample only.
  • Subjects with ferromagnetic objects lodged in body will be excluded, with the exception of family member subjects participating for clinical interview and blood sample only.
  • Schizophrenic patients who are judged to be incompetent to provide voluntary informed consent based on the ESC evaluation.
  • Any participant who would require an x-ray to rule out the presence of metal in their body prior to an MRI scan
05

Study design

Observational model
Family-based
Time perspective
Other
Enrollment
3,500 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • 1

    Controls

    Other: This is an observational study model that is family based

  • 2

    Patient Family

    Other: This is an observational study model that is family based

  • 3

    Patients

    Other: This is an observational study model that is family based

Interventions

  • OtherThis is an observational study model that is family based

    This is an observational study model that is family based

06

What researchers measure

Primary outcomes

  1. Smooth pursuit eye movement measures; P50 gating; PPI; Cognitive measures; P300 component of evoked potential; genetic markers

    Time frame: 10-13 hrs

07

Study locations

6 sites
  • Hartford Hospital- The Institute of Living
    Hartford, Connecticut 06106, United States
  • Center for Cognitive Medicine
    Chicago, Illinois 60612, United States
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21201, United States
  • University of Maryland, Baltimore
    Baltimore, Maryland 21228, United States
  • Wayne State University School of Medicine
    Detroit, Michigan 48201, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00666432
Lead sponsor
University of Maryland, Baltimore
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
MPRC (L.E. Hong, University of Maryland, Baltimore) — Principal investigator
First posted
Apr 24, 2008
Start date
May 2008
Primary completion
Sep 2012
Completion
Nov 22, 2019
Last update
May 3, 2021

Study contacts

Liyi E Hong, M.D.
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion